Aphria Inc. logo
Aphria Inc. APHA

Aphria Inc. Financial Ratios 2011-2025 | APHA

Annual Financial Ratios Aphria Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-13.1 -103.1 50.9 101.9 174.3 -5.8 - - - -

P/S

2.0 7.2 40.6 20.9 8.2 68.3 - - - -

EV/EBITDA

-117.4 -25.3 71.3 124.4 -72.6 -4.6 - - - -

PEG

-0.03 0.75 0.15 0.34 -1.63 0.1 - - - -

P/B

0.6 1.0 1.3 1.6 2.0 2.8 - - - -

P/CF

-4.2 -6.5 -6.7 -6.9 -12.7 -4.7 - - - -

ROE %

-4.60 -0.95 2.51 1.53 1.14 -49.03 - - - -

ROA %

-3.39 -0.68 2.24 1.33 1.10 -45.78 - - - -

ROCE %

-2.49 -3.81 1.10 0.69 -3.11 -50.01 - - - -

DSO

55.2 133.2 177.9 103.6 107.0 731.9 - - - -

DIO

206.8 165.1 418.2 451.7 310.4 -2585.4 - - - -

DPO

119.5 190.9 595.1 682.5 188.2 -1420.3 - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Aphria Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AC Immune SA AC Immune SA
ACIU
$ 2.8 2.19 % $ 229 M schweizSchweiz
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 2.49 -11.39 % $ 32.8 K usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.59 -4.08 % $ 98.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.12 -1.58 % $ 3.74 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 5.37 -20.68 % $ 194 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
argenx SE argenx SE
ARGX
$ 919.62 2.76 % $ 25 B niderlandNiderland
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 203.0 -3.72 % $ 5 B danmarkDanmark
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 4.64 -0.32 % $ 92 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.36 2.73 % $ 8.08 B australiaAustralia
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.29 -1.5 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.27 -1.38 % $ 10.3 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
AbbVie AbbVie
ABBV
$ 224.99 -0.01 % $ 398 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.22 -1.21 % $ 27.2 B germanyGermany
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 18.75 -0.48 % $ 2.76 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.92 -7.01 % $ 4.87 M usaUSA
Biogen Biogen
BIIB
$ 179.76 1.11 % $ 26.2 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 23.52 -2.22 % $ 1.94 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.45 -0.72 % $ 1.02 B canadaCanada
Cabaletta Bio Cabaletta Bio
CABA
$ 2.37 -2.67 % $ 2.77 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA